SCHEMBL4670664

SCHEMBL4670664

N#CCOc1ccc2cc(CN)ccc2c1-c1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ASIC3 Q9UHC3 1/20 0.40
ROCK1 Q13464 1/20 0.38
TAAR1 Q96RJ0 1/20 0.36
CSNK2A1 P68400 3/20 0.35
ALOX5 P09917 1/20 0.34
ALOX5AP P20292 2/20 0.33
FEN1 P39748 2/20 0.33
FFAR1 O14842 1/20 0.33
ESR1 P03372 1/20 0.33
ESR2 Q92731 1/20 0.33
CFD P00746 1/20 0.32
PLG P00747 1/20 0.32
PLAU P00749 1/20 0.32
F11 P03951 1/20 0.32
KLKB1 P03952 1/20 0.32
F7 P08709 1/20 0.32
TPSB2 P20231 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2D6 P10635 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4673957 0.88 ROCK1 (0.36) ROCK1CSNK2A1ALOX5SMN1; SMN2ALDH1A1
SCHEMBL4670539 0.88 ROCK1 (0.36) ROCK1TAAR1CSNK2A1
SCHEMBL4674157 0.85 MAOB (0.38) ROCK1PLGALDH1A1
SCHEMBL4672814 0.84 TDO2 (0.37) ROCK1CSNK2A1ALOX5
SCHEMBL4670662 0.81 PLAU (0.38) PLAUALDH1A1DPP4PDE4APDE4B
SCHEMBL4674130 0.79 ROCK1 (0.41) ASIC3ROCK1CSNK2A1LOXL2
SCHEMBL4673494 0.76 ROCK1 (0.38) ASIC3ROCK1TAAR1CSNK2A1ALOX5
SCHEMBL4672161 0.74 ESR1 (0.59) ASIC3ROCK1TAAR1CSNK2A1ALOX5
SCHEMBL4670306 0.70 ASIC3 (0.44) ASIC3ROCK1ALOX5FFAR1SMN1; SMN2
SCHEMBL4670537 0.69 CSNK2A2 (0.38) PLAU

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1397341-B1 6-(ARYL-AMIDO OR ARYL-AMIDOMETHYL)-NAPHTHALEN-2-YLOXY-ACIDIC DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 (PAI-1) WYETH CORP (US) 2008-08-06 EP disclosed
EP-1397341-A1 6-(ARYL-AMIDO OR ARYL-AMIDOMETHYL)-NAPHTHALEN-2-YLOXY-ACIDIC DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 (PAI-1) Wyeth (US) 2004-03-17 EP disclosed
US-6589970-B2 This invention provides novel compounds, pharmaceutical compositions and methods of treating thrombotic disorders in mammals, the compounds having the formula: WYETH 2003-07-08 US disclosed
US-20030045560-A1 6-(Aryl-amido or aryl-amidomethyl)-naphthalen-2-yloxy-acidic derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) WYETH 2003-03-06 US disclosed
WO-2003000649-A1 6-(ARYL-AMIDO OR ARYL-AMIDOMETHYL)-NAPHTHALEN-2-YLOXY-ACIDIC DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 (PAI-1) WYETH (US) 2003-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030045560-A1 6-(Aryl-amido or aryl-amidomethyl)-naphthalen-2-yloxy-acidic derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) SERPINC1, F11, SERPINE1 ASIC3 970/4885ROCK1 1602/4885TAAR1 601/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.